08.08.26 -- Pharmaceutical Online Newsletter - Best Of July

In March 2026, the FDA issued a new draft guidance titled Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection Guidance for Industry. Let's take a closer look.

A persistent gap remains between what Annex 1 requires and what facilities can demonstrate. Let's take a closer look at four common compliance failures.

U.S. Pharmacopeia General Chapter <665> went into effect May 1. One expert explains why complex bioprocessing equipment trains present a greater obstacle than you might think.

Translating EU GMP Annex 1 into consistent site-level practice is where most struggle. Hear why the global-to-local execution gap remains the biggest compliance challenge and what it takes to close it.

As drug modalities grow more complex, speed depends on smarter decisions. See how bioprocessing equipment choices play a larger role in enabling momentum than many teams realize.

Sterile manufacturing remains vital, with resilient supply chains preventing shortages. Industry and regulators prioritize integrity as demand surges, making it the fastest-growing pharmaceutical segment.